Giant Cell Tumor of Bone: Symptoms, Diagnosis, and Treatment

A Giant Cell Tumor of Bone (GCTB) is an osteolytic neoplasm arising predominantly in the epiphyseal region of mature long bones. Histologically, it is classified as benign but locally aggressive, meaning it exhibits significant capacity for bone resorption and local soft tissue infiltration:

• Benign Nature: More than 95% of cases show typical non-malignant histology and do not undergo systemic transformation.
• Malignant Transformation: Primary or secondary malignant GCTB (dedifferentiation into high-grade osteosarcoma or undifferentiated pleomorphic sarcoma) occurs in less than 2% of patients.
• Benign Pulmonary Implants: Approximately 1% to 3% of patients develop histologically benign lung nodules that follow an indolent clinical course.

GCTB displays distinct epidemiological and anatomical characteristics:

• Age Group: It peaks between 20 and 45 years of age, occurring almost exclusively after growth plate (physeal) closure. It is rare in skeletally immature pediatric patients.
• Gender Predilection: There is a slight female predominance (approximately 1.2:1).
• Predominant Anatomical Locations:
  • Around the knee (50%–60% of cases): The distal femur and proximal tibia represent the most common sites.
  • Distal radius: The second most frequent long bone location (approx. 10%), often displaying higher local recurrence rates.
  • Proximal humerus: Shoulder region.
  • Axial skeleton: The sacrum and vertebral bodies, representing surgically challenging locations.

Symptoms develop insidiously as the tumor hollows out structural trabeculae beneath the joint surface:

• Persistent, Deep Bone Pain: Discomfort localized adjacent to the affected joint, which worsens with mechanical weight-bearing and physical exertion, progressing over time to rest and nocturnal pain.
• Palpable Swelling or Mass: A firm, tender expansion over the bone contour with localized skin warmth due to increased tumor vascularity.
• Joint Stiffness & Effusion: Limited terminal flexion or extension with secondary reactive joint fluid accumulation.
• Pathological Fracture: Presenting symptom in 10% to 30% of patients, occurring during routine activities as the structural cortical shell collapses.

The Campanacci staging system is the international radiographic and surgical benchmark used to stratify local disease extent and determine operative strategy:

• Grade I (Latent / Inactive): Small, intraosseous lesion with well-demarcated margins, a thin rim of sclerotic bone, and an intact cortical shell.
• Grade II (Active): Moderately large, expansile osteolytic lesion causing marked cortical thinning without a sclerotic rim, but the periosteal envelope remains intact (most common presentation).
• Grade III (Aggressive): Rapidly expanding lesion showing complete cortical destruction, breakthrough of the periosteal barrier, and extension into adjacent soft tissue compartments or intra-articular structures.

Accurate diagnosis requires a multimodal staging and histological pathway:

• Plain Radiographs (X-ray): Demonstrates an eccentric, purely geographic lytic lesion originating in the epiphyseal/metaphyseal region and extending down to the subchondral plate, with a classic ‘soap-bubble’ trabecular appearance without tumor matrix mineralization.
• Magnetic Resonance Imaging (MRI): Essential to define the exact extent of intraosseous spread, joint cartilage integrity, and soft tissue margins, typically showing low-to-intermediate T1 and heterogeneous T2 signal.
• Computed Tomography (CT): Evaluates residual cortical thickness, fractures, and subchondral bone support.
• Core Needle Biopsy: Mandatory prior to any definitive intervention to demonstrate uniformly distributed, multinucleated osteoclast-like giant cells embedded within mononucleated stromal cells, and to definitively rule out osteosarcoma, brown tumors of hyperparathyroidism, or aneurysmal bone cysts (ABCs).

Extended intralesional curettage is the oncological gold standard for joint preservation in Campanacci Grade I and II lesions:

• Cortical Window: A generous cortical fenestration is cut over the tumor to provide complete visual access to all margins of the bone cavity.
• Gross Debridement: The vascular, fleshy tumor tissue is scooped out with specialized angled curettes.
• High-Speed Burr Drilling: A high-speed surgical burr is systematically applied to grind away an additional 2 to 3 mm of the peripheral cancellous walls, eliminating microscopic cellular extensions hidden within the bone trabeculae.
• Reconstruction & Fixation: The void is filled with polymethylmethacrylate (PMMA) bone cement, which provides immediate structural rigidity, often reinforced with locked plates and screws to prevent postoperative fracture and enable immediate weight-bearing.

Simple curettage alone yields unacceptable local recurrence rates approaching 50%. The routine addition of intraoperative local adjuvants drops recurrence to 10%–15%:

• Medical Phenol (70%): A chemical agent painted onto the cavity walls to induce protein coagulation and cell necrosis in microscopic tumor residuals, followed by an absolute alcohol wash for neutralization.
• Liquid Nitrogen Cryotherapy: Controlled sub-zero freezing cycles produce intracellular ice crystal formation and rapid cell lysis within the peripheral margin.
• Hydrogen Peroxide (3%): Provides mechanical cleansing, local hemostasis, and oxidative cytotoxicity.
• PMMA Thermal Cautery: The exothermic polymerization reaction of PMMA bone cement reaches temperatures between 60°C and 80°C, producing a localized thermal burn that kills residual tumor cells in the adjacent bone bed.

Joint-sparing curettage is not feasible in all clinical scenarios. Wide en-bloc resection is indicated when:

• The lesion is an aggressive Campanacci Grade III tumor with complete collapse and destruction of the subchondral bone and articular surface.
• There is a comminuted, displaced intra-articular pathological fracture where anatomical joint reconstruction is impossible.
• The patient experiences multiple local recurrences with extensive joint and soft tissue compromise.
• The tumor involves an anatomically expendable bone segment (such as the proximal fibula or distal ulna) that can be removed with zero functional deficit.
• Reconstruction involves implanting a modular tumor megaprosthesis (e.g., distal femoral or proximal tibial replacement) or structural osteoarticular allografts to restore limb stability and mobility.

Denosumab (Xgeva) is a fully human monoclonal antibody that specifically targets and inhibits RANKL, disrupting the signaling pathway that drives the formation and survival of osteoclast-like giant cells:

• Neoadjuvant Therapy: Administered for 3 to 6 months prior to surgery to halt bone osteolysis, induce a firm osteosclerotic rim, and shrink soft tissue components, converting difficult lesions into candidates for joint-preserving curettage.
• Surgically Inaccessible Lesions: Primary management for tumors located in the sacrum, spine, or skull base where complete surgical resection risks unacceptable neurological morbidity.
• Metastatic & Recurrent Disease: Long-term disease control for recurrent unresectable lesions and benign lung metastases.
• Clinical Precaution: Patients require routine monitoring of serum calcium to prevent hypocalcemia, alongside dental evaluations to mitigate the risk of medication-related osteonecrosis of the jaw (MRONJ).

While recurrence rates after extended curettage with adjuvants and cementation remain low (10% to 15%), over 80% of local recurrences occur within the first 24 to 36 months. Strict oncologic surveillance is required:

• Years 1 to 2: Clinical evaluations and orthogonal plain radiographs of the operated bone every 3 to 4 months to assess cement-bone interfaces for radiolucent lines indicating recurrence.
• Years 3 to 5: Clinical and radiographic check-ups every 6 months.
• Pulmonary Monitoring: Plain chest X-rays or low-dose chest CT scans every 6 to 12 months for 5 years to screen for asymptomatic benign lung metastases.